Want to join the conversation?
$EW now sees 2016 sales to be at high end of its prior $2.7-3Bil range based on strong 1H results, expected 3Q approval of intermediate risk in the U.S., and momentum of therapy adoption globally. $EW raised FY16 adjusted EPS outlook to $2.78-2.88 from prior range of $2.67-2.77. For 3Q16, $EW sees sales of $720-760MM and adjusted EPS of $0.62-0.68.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.